NASDAQ: BYSI · Life Sciences · 7 alerts · CIK 1677940
Share price
$0.5788Close, Nov 16
Market cap
$24M
Shares outstanding
41.41MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BeyondSpring Inc. filings on SEC EDGAR ↗
BeyondSpring Inc. reported a significant net income of $50.5 million for the quarter ended September 30, 2026, primarily driven by a $53.7 million gain on the sale of subsidiary interests and the deconsolidation of discontinued operations. Despite this one-time gain, the company continues to experience operating losses from continuing operations, totaling $2.1 million for the quarter, as it remains in the development stage with no revenue.
BeyondSpring reported Q3 2026 financial results and highlighted that the FDA granted Fast Track designation for Plinabulin in combination with docetaxel for certain NSCLC patients. The company also completed a strategic transaction with Biolin to fund approximately half of the enrollment for the Phase 3 DUBLIN-4 trial.
Term
Q3 2026
“The FDA’s Fast Track designation underscores the significant unmet need for new treatment options for NSCLC patients without AGA and progressing after immune checkpoint inhibitor therapy, where docetaxel is still the standard of care.”
Min Qiu, Chief Executive Officer of BeyondSpring
“With an FDA-aligned Phase 3 design and a strategic transaction with Biolin to support approximately half of DUBLIN-4’s planned 442-patient enrollment, generating quality data from China, we remain focused on advancing the study toward its prespecified interim analysis at 221 progression-free survival events.”